Hubertus von Baumbach, membro della Boehringer Ingelheim¯s consiglio di amministratori delegati, parla dopo la firma di un accordo per la fabbricazione biopharmaceutica
Hubertus von Baumbach, member of Boehringer Ingelheim¯s board of managing directors, speaks after signing an agreement to manufacture biopharmaceuticals for Beijing-based biotech company BeiGene in Shanghai, China, 2 September 2014. Germany¯s Boehringer Ingelheim yesterday (2 September 2014) signed an agreement to manufacture biopharmaceuticals for Beijing-based biotech company BeiGene in Shanghai, which has been studying plans to allow contract manufacturing of biomedicine. BI¯s newly invested Zhangjiang facility in Shanghai is expected to start producing cancer drugs for BeiGene next year to be used for clinical research purposes, the companies said. The 500 million yuan (US$81.3 million) facility will eventually become BI¯s fourth manufacturing plant to support the global market after Germany, Austria and the US. Shanghai has been considering since 2013 to be the first in China to introduce biophamaceuticals contract manufacturing organization (CMO), which lets a contract manufacturer act as a producer and shipper on behalf of a hiring company. Hubertus von Baumbach, member of BI¯s board of managing directors, said the firm is confident of a CMO license for the Zhangjiang facility, a joint investment with Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co, which started last year.
